Stockscreener 앱 받기
6.11
9.35%
-0.63
전일 마감가:
$6.74
열려 있는:
$6.73
하루 거래량:
154.41K
Relative Volume:
2.03
시가총액:
$59.17M
수익:
$1.15M
순이익/손실:
$-46.90M
주가수익비율:
-1.2176
EPS:
-5.0182
순현금흐름:
$-42.37M
1주 성능:
-21.06%
1개월 성능:
-5.86%
6개월 성능:
-60.96%
1년 성능:
-50.53%
1일 변동 폭
$6.025
$6.8477
1주일 범위
$6.025
$8.25
52주 변동 폭
$5.31
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
6.11 | 59.17M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer - Stock Titan
Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere - Stock Titan
Seres Therapeutics (MCRB) director receives 6,500 stock options at $7.14 strike - Stock Titan
Seres Therapeutics (MCRB) awards 7,500 stock options to company officer Marella Thorell - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson - Stock Titan
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study - Yahoo Finance
Seres Therapeutics, Inc. Amends and Restates 2025 Incentive Award Plan in SEC 8-K Filing - Minichart
Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary - Quartr
Seres Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase - Stock Titan
Seres Therapeutics (MCRB) Q4 2025 earnings summary - Quartr
Why Is Seres Therapeutics Stock Falling Today?Seres Therapeutics (NASDAQ:MCRB) - Benzinga
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related AndropilatisSlideshow (NASDAQ:MCRB) 2026-07-08 - Seeking Alpha
Seres Therapeutics reports positive early SER-155 data - grafa.com
Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis - BioWorld News
MCRB: All proposals, including director elections and incentive plan amendment, were approved - TradingView
Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell - Moomoo
Seres Therapeutics reports positive SER-155 trial results - TipRanks
Seres Therapeutics (NASDAQ: MCRB) highlights promising SER-155 data and limited cash runway - Stock Titan
Seres Therapeutics unveils promising IST results for SER-155 in irEC patients - Traders Union
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment - The Manila Times
Seres Therapeutics outlines its microbiome drug strategy as MCRB works to regain traction - ad-hoc-news.de
Price to book forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
MCRBSeres Therapeutics Inc Dividends - Finviz
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
Form 4 Seres Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Seres Therapeutics (NASDAQ: MCRB) director receives 7,508-share stock option grant - Stock Titan
Seres Therapeutics (NASDAQ: MCRB) director awarded 7,508 stock options at $7.94 - Stock Titan
Seres Therapeutics (MCRB) director awarded 7,508 stock options vesting by 2027 - Stock Titan
Clostridium Difficile Infections Market Forecast Signals Robust Industry Growth Through 2034 – DelveInsight | Seres Therapeutics, Nestlé Health Science, Adiso Therapeutics, Deinove, Acurx Pharma - Barchart.com
Price to sales forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Price to earnings forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Seres Therapeutics to Host Webcast on July 8, 2026, to - GlobeNewswire
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Insulet analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN
H.C. Wainwright Initiates Seres Therapeutics(MCRB.US) With Buy Rating, Announces Target Price $12 - Moomoo
MCRB Initiates Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating By Investing.com - Investing.com Nigeria
HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target - Moomoo
Seres Therapeutics Inc Cash Flow – DUS:1S90 - TradingView
EBITDA per share of Seres Therapeutics Inc – DUS:1S90 - TradingView
Return on assets % of Seres Therapeutics Inc – DUS:1S90 - TradingView
Total common shares outstanding of Seres Therapeutics Inc – DUS:1S90 - TradingView
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc (MCRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Seres Therapeutics Inc (MCRB) Institutional Confidence - TradingKey
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):